Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IM Cannabis Corp. - Common Shares (NQ: IMCC )

2.110 -0.320 (-13.17%)
Streaming Delayed Price Updated: 11:25 AM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IM Cannabis Corp. - Common Shares

< Previous 1 2 3 4 5 Next >
IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3
International medical cannabis company IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial results for the third quarter ended Sept. 30, 2024. The company reported revenue... 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Supply Chain
A Peek at IM Cannabis's Future Earnings
Via Benzinga
Topics Cannabis
Exposures Cannabis
Canopy Growth And Other Top Cannabis Companies To Report Earnings: Will Results Get Pot Stocks On Track Following Post-Election Dip?
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) will report the second quarter of fiscal year 2025 ended Sept. 30, before financial markets open on Friday, Nov. 8, 2024. IM Cannabis Corp. (CSE:... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Ever-Evolving Cannabis Industry: These Are Latest Leadership Changes You Should Know About
The U.S. Hemp Roundtable made headlines in early September as its board of directors welcomed two distinguished leaders from the hemp beverage sector to its officer ranks. New York's chief equity... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Earnings Scheduled For November 14, 2024
Via Benzinga
IM Cannabis' $1.6M Non-Brokered Private Placement Offering, Here's What Investors Need To Know
Medical cannabis company with operations in Israel and Germany, IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC), intends to undertake a non-brokered private placement offering of up to $1,613,000 through... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
How Cannabis Legalization In Germany Boosted This Company's Revenue, Will Spain's Medical Marijuana Framework Do The Same?
Spain's Ministry of Health revealed this week a draft royal decree for public consultation, outlining the suggested regulations for prescribing cannabis-based medications, reported Business of... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
IMCC Stock Earnings: IM Cannabis Beats EPS, Beats Revenue for Q2 2024
IMCC stock results show that IM Cannabis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
IM Cannabis Soars: German Sales Surge 200% In First 3 Months Post-Legalization, Q2 Revenue Up 12% YoY
The company, announced its financial results Wednesday for the second quarter ended June 30, 2024, revealing a 12% year-over-year increase in revenue to CA$14.8 million in the second quarter of 2023.... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
IM Cannabis, Organigram And Other Hot Cannabis Stocks Soon To Report Earnings, What Investors Need To Know Now
Medical cannabis company IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), with operations in Israel and Germany, will report operational and financial results for the second quarter of 2024 ended June 30,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
European Cannabis Companies Race To The Nasdaq: $1B In Tax Break On The Horizon
Some European cannabis companies are already planning initial public offerings (IPOs) on the Nasdaq, encouraged by the prospect of a less restrictive regulatory environment. The potential rescheduling... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
IM Cannabis Shares Surge 586% After 6:1 Consolidation: What Investors Need To Know
IM Cannabis Corp. (NASDAQ: IMCC), a leading medical marijuana company announced that its common shares are trading on a 6:1 post-consolidated basis. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
IM Cannabis Announces Major Share Consolidation Plan: What Investors Need To Know
IM Cannabis announces a share consolidation effective July 12, aiming to enhance marketability and streamline shares. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Global Weed Business: Flora Buys Australian Vaporizers As IM Cannabis Doubles Down On Germany
Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF) said on Wednesday the sale of Australian Vaporizers Pty Ltd., its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ:... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Weed Industry Celebrates Biden's Rescheduling Move: 'Most Monumental Cannabis Reform In Half A Century'
Cannabis companies and advocates applaud President Biden's announcement to reschedule and legalize cannabis, calling it a major leap forward and opportunity to correct long-standing wrongs and improve... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Weed Stocks Rally After Biden Makes Marijuana Reclassification Announcement
Shares of marijuana growers and related companies are trading higher Thursday after President Biden announced that the Department of Justice has moved to reclassify marijuana from a Schedule I... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Flora Growth Goes Back To Net Loss In Q1, Positive About 'Landmark Reform' In The US, Focuses On Europe
Via Benzinga
IMCC Stock Earnings: IM Cannabis Misses EPS, Misses Revenue for Q1 2024
IMCC stock results show that IM Cannabis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
IM Cannabis Doubles Down On Germany Following Legalization Policy Change, Reports YoY Drop In Q1 Gross Profit And Revenue
IM Cannabis reported a 13% sequential increase in revenue for the three months ended March 31, 2024, hitting CA$10.7 million ($7.8 million). That is, however, a 4% decrease compared to the same quarter... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday! 
Via InvestorPlace
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What's Going On With IM Cannabis Stock?
Cannabis stocks soared Tuesday following reports that the DEA will move to reschedule marijuana from a Schedule I to a Schedule III substance. IM Cannabis shares are holding the gains, while larger... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Why Is CVRx (CVRX) Stock Down 32% Today?
CVRx stock is falling hard on Wednesday after the company posted EPS and revenue misses in its earnings report for Q1 2024. 
Via InvestorPlace
Why Is Plutonian Acquisition (PLTN) Stock Up 27% Today?
Plutonian Acquisition stock is in the rise Wednesday with heavy trading of PLTN shares alongside results from a special shareholder meeting. 
Via InvestorPlace
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is IM Cannabis (IMCC) Stock Up 49% Today?
IM Cannabis stock is up on Wednesday with heavy trading of IMCC shares on news the Biden Administration plans to reclassify marijuana. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news for Wednesday morning! 
Via InvestorPlace
Puff, Puff, Invest: 3 Top Cannabis Stock Picks to Celebrate 4/20
As the marijuana landscape continues to evolve, discover the green potential in these cannabis stocks for 4/20. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.